vs
Side-by-side financial comparison of Invivyd, Inc. (IVVD) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $5.5M, roughly 3.1× Taysha Gene Therapies, Inc.). Invivyd, Inc. runs the higher net margin — -64.3% vs -507.8%, a 443.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 24.5%).
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
IVVD vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.2M | $5.5M |
| Net Profit | $-11.1M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -73.0% | -516.0% |
| Net Margin | -64.3% | -507.8% |
| Revenue YoY | 24.5% | 171.3% |
| Net Profit YoY | 40.0% | -48.3% |
| EPS (diluted) | $0.02 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.2M | $5.5M | ||
| Q3 25 | $13.1M | $0 | ||
| Q2 25 | $11.8M | $2.0M | ||
| Q1 25 | $11.3M | $2.3M | ||
| Q4 24 | $13.8M | $2.0M | ||
| Q3 24 | $9.3M | $1.8M | ||
| Q2 24 | $2.3M | $1.1M | ||
| Q1 24 | $0 | $3.4M |
| Q4 25 | $-11.1M | $-27.9M | ||
| Q3 25 | $-10.5M | $-32.7M | ||
| Q2 25 | $-14.7M | $-26.9M | ||
| Q1 25 | $-16.3M | $-21.5M | ||
| Q4 24 | $-18.4M | $-18.8M | ||
| Q3 24 | $-60.7M | $-25.5M | ||
| Q2 24 | $-47.2M | $-20.9M | ||
| Q1 24 | $-43.5M | $-24.1M |
| Q4 25 | -73.0% | -516.0% | ||
| Q3 25 | -84.0% | — | ||
| Q2 25 | -127.8% | -1347.1% | ||
| Q1 25 | -149.7% | -930.5% | ||
| Q4 24 | -139.1% | -985.8% | ||
| Q3 24 | -670.0% | -1448.4% | ||
| Q2 24 | -2175.2% | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | -64.3% | -507.8% | ||
| Q3 25 | -79.7% | — | ||
| Q2 25 | -124.4% | -1353.6% | ||
| Q1 25 | -144.1% | -935.2% | ||
| Q4 24 | -133.5% | -929.0% | ||
| Q3 24 | -653.1% | -1427.5% | ||
| Q2 24 | -2086.9% | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | $0.02 | $-0.08 | ||
| Q3 25 | $-0.06 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.09 | ||
| Q1 25 | $-0.14 | $-0.08 | ||
| Q4 24 | $-0.14 | $-0.07 | ||
| Q3 24 | $-0.51 | $-0.10 | ||
| Q2 24 | $-0.40 | $-0.09 | ||
| Q1 24 | $-0.38 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.7M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $241.5M | $246.9M |
| Total Assets | $276.9M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.7M | $319.8M | ||
| Q3 25 | $85.0M | $297.3M | ||
| Q2 25 | $34.9M | $312.8M | ||
| Q1 25 | $48.1M | $116.6M | ||
| Q4 24 | $69.3M | $139.0M | ||
| Q3 24 | $106.9M | $157.7M | ||
| Q2 24 | $147.9M | $172.7M | ||
| Q1 24 | $189.4M | $124.0M |
| Q4 25 | $241.5M | $246.9M | ||
| Q3 25 | $93.1M | $219.0M | ||
| Q2 25 | $42.8M | $248.7M | ||
| Q1 25 | $54.1M | $55.1M | ||
| Q4 24 | $67.5M | $71.5M | ||
| Q3 24 | $83.2M | $88.8M | ||
| Q2 24 | $140.6M | $108.9M | ||
| Q1 24 | $178.5M | $53.8M |
| Q4 25 | $276.9M | $343.3M | ||
| Q3 25 | $139.2M | $316.6M | ||
| Q2 25 | $89.1M | $333.3M | ||
| Q1 25 | $103.7M | $138.4M | ||
| Q4 24 | $129.5M | $160.4M | ||
| Q3 24 | $161.9M | $180.2M | ||
| Q2 24 | $177.3M | $200.4M | ||
| Q1 24 | $215.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.5M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.5M | $-26.7M | ||
| Q3 25 | $-8.3M | $-24.2M | ||
| Q2 25 | $-13.3M | $-20.2M | ||
| Q1 25 | $-21.1M | $-22.0M | ||
| Q4 24 | $-37.6M | $-18.3M | ||
| Q3 24 | $-41.1M | $-21.6M | ||
| Q2 24 | $-41.6M | $-21.5M | ||
| Q1 24 | $-50.2M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | $-13.3M | — | ||
| Q1 25 | $-21.3M | — | ||
| Q4 24 | $-37.6M | $-18.3M | ||
| Q3 24 | $-41.1M | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | $-50.4M | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -112.9% | — | ||
| Q1 25 | -188.2% | — | ||
| Q4 24 | -272.2% | -905.5% | ||
| Q3 24 | -441.6% | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.0% | 18.1% | ||
| Q1 24 | — | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
